Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 4/20 | 0.94 |
| ▸ | KIT known ✓ | P10721 | 4/20 | 0.94 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 18/20 | 0.94 |
| ▸ | CSF1R | P07333 | 17/20 | 0.94 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.94 |
| ▸ | RET | P07949 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 2/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20484791 | 1.00 | FLT3 (0.94) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698701 | 0.97 | FLT3 (1.00) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698939 | 0.93 | CSF1R (0.80) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698774 | 0.92 | CSF1R (0.80) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698995 | 0.92 | FLT3 (0.80) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698732 | 0.92 | FLT3 (0.79) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL29766467 | 0.92 | FLT3 (0.94) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1698589 | 0.92 | FLT3 (0.94) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL15388761 | 0.91 | FLT3 (0.78) | FLT3CSF1RPDGFRBKITPDGFRA | |
| SCHEMBL1699067 | 0.91 | FLT3 (0.80) | FLT3CSF1RPDGFRBKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-21 | — | — | US | claimed |
| CN-110636861-B | Synergistic therapy comprising a small molecule CSF-1R inhibitor and an agonistic antibody that specifically binds CD40 for the treatment of cancer | 詹森生物科技公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022040606-A1 | COMPOSITIONS AND METHODS TO REDUCE NEUROINFLAMMATION | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2022-02-24 | — | — | WO | disclosed |
| US-9296722-B2 | Azolyl urea compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-03-29 | — | — | US | disclosed |
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2011150198-A1 | AZOLYL UREA COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310357-A1 | Azolyl Urea Compounds and Methods of Use Thereof | CSF1R, CSF3R, ARG1 | PDGFRB 733/4885KIT 310/4885KDR 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.